Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 2/3 1

Status

Active not recruiting 2Completed 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Myeloid 3Sarcoma 1Other hematologic neoplasm 1CNS 1

Conditions

Myelodysplastic Syndromes 3Recurrence 1Primary Myelofibrosis 1Myeloproliferative Disorders 1Leukemia, Myeloid, Acute 1

Interventions

fludarabine phosphate 113Cyclophosphamide 97Whole-Body Irradiation 82Mycophenolic Acid 79fludarabine 74Tacrolimus 69Busulfan 68Azacitidine 62Peripheral Blood Stem Cell Transplantation 59Melphalan 48Cytarabine 48Antilymphocyte Serum 47Methotrexate 45Cyclosporine 45Filgrastim 39Imatinib Mesylate 37Granulocyte Colony-Stimulating Factor 37Decitabine 35nilotinib 34thymoglobulin 31ruxolitinib 29Thiotepa 27Stem Cell Transplantation 23Clofarabine 22Alemtuzumab 21Rituximab 19Dasatinib 19Cord Blood Stem Cell Transplantation 19sargramostim 17Sirolimus 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has results × imetelstat × Myeloid × Clear all
NCT05583552 2026-05-12

IMpress

GCP-Service International West GmbH

Phase 2 Active not recruiting
46 enrolled 21 charts
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT02598661 2026-01-05

Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

Geron Corporation

Phase 2/3 Active not recruiting
289 enrolled 35 charts 1 FDA
Myeloid

Myelodysplastic Syndromes, Recurrence

NCT01731951 2021-09-21

Imetelstat Sodium in Treating Participants With Primary or Secondary Myelofibrosis

Geron Corporation

Phase 2 Completed
80 enrolled 31 charts
Myeloid

Myelodysplastic Syndromes, Myeloproliferative Disorders, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡